BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by Northern Trust Corp

Key Points

• Northern Trust Corp reduced its holdings in BioCryst Pharmaceuticals by 2.5% in the 1st quarter, now holding approximately $14.66 million worth of shares.
• BioCryst Pharmaceuticals reported a 49.5% revenue increase year-over-year for the last quarter, with earnings per share of $0.15, surpassing analysts' expectations.
• Equities analysts have shown positive sentiment, with several raising their target prices, resulting in a consensus rating of "Moderate Buy" for the stock.

Northern Trust Corp lowered its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 2.5% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,955,258 shares of the biotechnology company's stock after selling 49,653 shares during the period. Northern Trust Corp owned about 0.93% of BioCryst Pharmaceuticals worth $14,664,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of BCRX. Allianz Asset Management GmbH grew its stake in BioCryst Pharmaceuticals by 9.6% during the 1st quarter. Allianz Asset Management GmbH now owns 13,700 shares of the biotechnology company's stock valued at $103,000 after acquiring an additional 1,200 shares in the last quarter. SG Americas Securities LLC grew its stake in BioCryst Pharmaceuticals by 5.2% during the 1st quarter. SG Americas Securities LLC now owns 43,496 shares of the biotechnology company's stock valued at $326,000 after acquiring an additional 2,146 shares in the last quarter. Mariner LLC grew its stake in BioCryst Pharmaceuticals by 32.1% during the 4th quarter. Mariner LLC now owns 13,258 shares of the biotechnology company's stock valued at $100,000 after acquiring an additional 3,224 shares in the last quarter. Quantinno Capital Management LP grew its stake in BioCryst Pharmaceuticals by 38.2% during the 4th quarter. Quantinno Capital Management LP now owns 14,828 shares of the biotechnology company's stock valued at $112,000 after acquiring an additional 4,097 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new stake in BioCryst Pharmaceuticals during the 1st quarter valued at about $32,000. Hedge funds and other institutional investors own 85.88% of the company's stock.

Analyst Upgrades and Downgrades

BCRX has been the topic of several recent analyst reports. Royal Bank Of Canada reiterated an "outperform" rating and issued a $13.00 target price on shares of BioCryst Pharmaceuticals in a report on Monday, June 30th. Bank of America boosted their target price on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a "buy" rating in a report on Tuesday, July 1st. Wall Street Zen upgraded shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, July 26th. Needham & Company LLC reiterated a "buy" rating and issued a $17.00 target price on shares of BioCryst Pharmaceuticals in a report on Monday, August 4th. Finally, Wedbush boosted their target price on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an "outperform" rating in a report on Monday, June 30th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $16.70.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX stock traded down $0.15 during trading hours on Tuesday, hitting $8.05. The company had a trading volume of 365,037 shares, compared to its average volume of 3,684,146. The company's fifty day moving average is $8.51 and its 200 day moving average is $8.74. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $6.01 and a fifty-two week high of $11.31. The stock has a market capitalization of $1.69 billion, a PE ratio of -44.75, a price-to-earnings-growth ratio of 1.88 and a beta of 1.13.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.03 by $0.12. The company had revenue of $163.35 million during the quarter, compared to analyst estimates of $149.59 million. During the same quarter in the prior year, the company posted ($0.06) earnings per share. The business's revenue was up 49.5% compared to the same quarter last year. Equities analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

Insider Activity at BioCryst Pharmaceuticals

In other news, Director Theresa Heggie sold 70,000 shares of the company's stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total value of $595,700.00. Following the transaction, the director directly owned 65,352 shares in the company, valued at approximately $556,145.52. This represents a 51.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 5.10% of the company's stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.